ALDH2 polymorphism, associated with attenuating negative symptoms in patients with schizophrenia treated with add-on dextromethorphan

Journal of Psychiatric Research
Sheng-Yu LeeRu-Band Lu

Abstract

Increasing the evidence of inflammation's contribution to schizophrenia; using anti-inflammatory or neurotrophic therapeutic agents to see whether they improve schizophrenia treatment. Dextromethorphan (DM), a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist, might protect monoamine neurons. Whether treating schizophrenia with risperidone plus add-on DM is more effective than risperidone (RISP) alone, and the association between the ALDH2 polymorphism and treatment response were investigated. A double-blind study in which patients with schizophrenia were randomly assigned to the RISP + DM (60 mg/day; n = 74) or the RISP + Placebo (n = 75) group. The Positive and Negative Syndrome Scale (PANSS) and the Scale for the Assessment of Negative Symptoms (SANS) scores were used to evaluate clinical response during weeks 0, 1, 2, 4, 6, 8, and 11. The genotypes of the ALDH2 polymorphism were determined using polymerase chain reactions plus restriction fragment length polymorphism analysis. A generalized estimating equation was used to analyze the effects of ALDH2 polymorphism on the clinical performance of DM. PANSS and SANS scores were significantly lower in both groups after 11 weeks of treatment. SANS total scores were ...Continue Reading

References

Sep 1, 1977·Agents and Actions·S C WangM C Wallenstein
Apr 1, 1992·Pharmacogenetics·D P Agarwal, H W Goedde
Feb 1, 1982·Journal of Neurochemistry·H Pettersson, O Tottmar
Jul 1, 1982·Archives of General Psychiatry·N C Andreasen
Feb 19, 2002·Immunology·Rob C Aalberse, Janine Schuurman
Jun 4, 2002·The American Journal of Psychiatry·Norbert MüllerMarkus J Schwarz
May 4, 2004·The American Journal of Psychiatry·Anil K MalhotraJames L Kennedy
Feb 15, 2005·BMC Medical Genetics·Daniel R Hanson, Irving I Gottesman
Aug 10, 2005·Alcoholism, Clinical and Experimental Research·Friedrich M WurstUNKNOWN International Society for Biomedical Research on Alcoholism
Sep 13, 2005·Parkinsonism & Related Disorders·Carlos BarciaMaría-Trinidad Herrero
Feb 14, 2006·Schizophrenia Bulletin·Alan S Brown
Feb 17, 2006·Schizophrenia Bulletin·Brian KirkpatrickStephen R Marder
Jul 17, 2008·Nature Reviews. Neuroscience·Florian Holsboer
Jun 1, 2006·Nutrition Research Reviews·C Sugden
Jul 1, 2009·Pharmacology & Therapeutics·Sonja Horstmann, Elisabeth B Binder
Jul 2, 2009·Toxicological Sciences : an Official Journal of the Society of Toxicology·Yang-Ming TsengLi-Yu Tsai
Feb 23, 2010·Journal of Affective Disorders·Georgina M HosangAnne E Farmer
Jun 26, 2010·Pharmacogenetics and Genomics·Sheng-Yu LeeRu-Band Lu
Dec 15, 2010·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Stefan SmesnyGregor E Berger
Feb 5, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hyo-Jung KwonBin Gao
Jul 25, 2014·Nature·UNKNOWN Schizophrenia Working Group of the Psychiatric Genomics Consortium

❮ Previous
Next ❯

Citations

Jul 5, 2016·Current Treatment Options in Psychiatry·Gary RemingtonMargaret Hahn
Jul 12, 2017·Biological Research for Nursing·Rose Mary Xavier, Allison Vorderstrasse

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here